Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Szimbólum: 002693.SZ
SHZ
5.69
CNYMai piaci árfolyam
-39.5632
P/E arány
2.2749
PEG-arány
2.36B
MRK Cap
- 0.00%
DIV hozam
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Pénzügyi kimutatások
Mérleg
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 31.9 | 146 | 77 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 28.5 | 133.8 | 55.4 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 16.4 | 41 | 33.1 | |||||||||||||||
balance-sheet.row.inventory | 0 | 74.3 | 65.4 | 55.2 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 0.2 | 0 | 0.1 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 135.2 | 252.4 | 165.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 457.6 | 471.8 | 504.7 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 171.8 | 164.9 | 156.9 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 171.8 | 164.9 | 156.9 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 10 | 8.8 | 17.3 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 1.5 | 1 | 1 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 27.1 | 12.2 | 9.1 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 668 | 658.6 | 689.1 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 803.2 | 911 | 854.6 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 17.1 | 15.5 | 17.2 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 10.1 | 205.3 | 0.3 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 3.7 | 12.8 | 7.2 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 135 | 0 | 167 | |||||||||||||||
Deferred Revenue Non Current | 0 | 8 | 7.6 | 8.9 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 2 | 73.6 | 1.8 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 145.7 | 10.7 | 179.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 285.6 | 330.1 | 287.8 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 34.4 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 416.7 | 414.7 | 412 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | -347 | -296.2 | -305.2 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -0.4 | 87.2 | 82.2 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 367.6 | 307.9 | 292.9 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 471.5 | 513.5 | 481.8 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 803.2 | 911 | 854.6 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 46.2 | 67.4 | 84.9 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 517.6 | 580.9 | 566.8 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 10 | 133.8 | 55.4 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 145.1 | 205.3 | 167.3 | |||||||||||||||
balance-sheet.row.net-debt | 0 | 141.7 | 193.1 | 145.6 |
Cash Flow kimutatás
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -8.5 | -40.8 | -79.9 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 57.5 | 54.3 | 57.1 | ||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 6.9 | 7.2 | -1.2 | ||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -4.5 | 14.9 | -12.2 | ||||||||||||||
cash-flows.row.account-receivables | 0 | -13.8 | 5.4 | 39.8 | ||||||||||||||
cash-flows.row.inventory | 0 | -9.9 | -4.8 | -4.3 | ||||||||||||||
cash-flows.row.account-payables | 0 | 19.6 | 13.8 | -48.9 | ||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -25.8 | -12.5 | 24.5 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.acquisitions-net | 0 | 27 | 21.7 | 53.6 | ||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -471 | -256.2 | -637.2 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 391.9 | 299.2 | 615.3 | ||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -51.6 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -85.1 | 33 | -71.5 | ||||||||||||||
cash-flows.row.debt-repayment | 0 | -12 | -55.3 | -1.8 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | 0 | -11.1 | -9.1 | -9.8 | ||||||||||||||
cash-flows.row.other-financing-activites | 0 | 68.1 | 23.8 | 57 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 44.9 | -40.6 | 45.4 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0.1 | -0.1 | -0.3 | ||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -14.8 | 15.8 | -36.9 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 6.8 | 21.6 | 5.8 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 21.6 | 5.8 | 42.7 | ||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 25.2 | 23.6 | -10.5 | ||||||||||||||
cash-flows.row.capital-expenditure | 0 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.free-cash-flow | 0 | -7.8 | -8.1 | -62.1 |
Eredménykimutatás sor
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 235.9 | 274.8 | 320.3 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 74.9 | 88.3 | 81.4 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 161.1 | 186.5 | 238.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.2 | 63.2 | 69 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 183.4 | 215.8 | 282.7 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 258.3 | 304.1 | 364.1 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0.1 | 0.1 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 9.6 | 11.2 | 9 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -50.6 | 15.6 | 2 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.2 | 63.2 | 69 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -50.6 | 15.6 | 2 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 9.6 | 11.2 | 9 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 52.7 | 57.5 | 54.3 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | -73.2 | -24.5 | -42.3 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | -73 | -8.9 | -40.4 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | -1 | -0.4 | 0.4 | |||||||||||||||
income-statement-row.row.net-income | 0 | -50.7 | -8.5 | -40.8 |
Gyakran ismételt kérdés
Mi a Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) az összes eszköz?
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) az összes eszköz 803248121.000.
Mekkora a vállalkozás éves bevétele?
Az éves bevétel N/A.
Mennyi a cég haszonkulcsa?
A cég haszonkulcsa 0.654.
Mennyi a vállalat szabad cash flow-ja?
A szabad pénzáramlás -0.103.
Mi a vállalati nettó haszonkulcs?
A nettó haszonkulcs -0.324.
Mennyi a vállalat teljes bevétele?
A teljes bevétel -0.443.
Mi a Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) nettó profit (nettó nyereség)?
A nettó nyereség (nettó bevétel) -50741578.370.
Mennyi a cég teljes adóssága?
Az összes adósság 145050750.000.
Mi a működési költségek száma?
A működési költségek 183423820.000.
Mennyi a cég készpénzállománya?
A vállalati pénzeszközök 0.000.